Histiocytic sarcoma (HS), a rare hematological malignancy, is an aggressive neoplasm that responds poorly to therapy. The molecular etiology and pathology of this disease remain unclear, hampering the development of an effective therapy, and there remains a need for more, and more realistic, animal models. HS cells typically show a histiocytic (ie, tissue macrophage-like) morphology and express histiocyte/macrophage markers in the absence of lymphocyte markers. In this study, we report that Dok-1 À/À Dok-2 À/À Dok-3 À/À mice develop HS, but do not exhibit elevated incidence of other types of tumors. These mutant mice showed earlier mortality than wild-type (WT) or the other mutant mice, and this mortality was associated with HS. In total, 17 of 21 tumor-bearing Dok-1
Histiocytic sarcoma (HS) is a malignant proliferation of cells showing morphological and immunophenotypic features of mature histiocytes, which represent tissue-resident macrophages.
1,2 Until recently, HS, which was also known as malignant histiocytosis, was often confused with anaplastic large B-cell lymphoma or with other malignant lymphomas. However, it has been established that true HS is a distinct and rare disease that is only about 0.1% as frequent as malignant lymphomas, which can be identified by the presence of B-or T-cell markers and/or CD30. 2 By definition, HS is negative for lymphocyte markers, but positive for histiocyte/macrophage markers such as CD163 in humans.
1, 2 The tumor comprises a diffuse noncohesive proliferation of large cells, round to oval in shape, with abundant, eosinophilic cytoplasm and nuclear atypia. HS is an aggressive neoplasm with most patients dying of progressive disease. Patients may present with a solitary mass of HS, which is predictive of a relatively favorable outcome, but some patients show a systemic pattern of tumor spread.
1,2 As the molecular etiology of this disease is unknown, the development of rational therapeutics has been difficult. Although the generation of animal models is an essential step for the study of etiology, the paucity of mouse models that represent aggressive HS has remained an outstanding problem.
We and others previously identified Dok-1 as a common substrate of protein-tyrosine kinases (PTKs) including BcrAbl, a cause of chronic myelogenous leukemia, 3, 4 and we further demonstrated that Dok-1 is a negative regulator of PTK-mediated proliferation and transformation of cells. 5, 6 Indeed, mice lacking both Dok-1 and its closest homolog Dok-2 developed a myeloproliferative disorder with a nonaggressive phenotype. 7, 8 It is believed that Dok-1 and Dok-2 have virtually identical roles in myeloid lineages. [7] [8] [9] The Dok family consists of seven members, Dok-1 to Dok-7, which share structural similarities characterized by the NH 2 -terminal pleckstrin homology and phosphotyrosinebinding domains, followed by the src homology 2 target motifs in the COOH-terminal moiety, suggesting an adaptor function. 3, 4, [10] [11] [12] [13] [14] Among these members, only Dok-1, Dok-2, and Dok-3 are preferentially expressed in hematopoietic cells, or myeloid cells in particular, and comprise a closely related subgroup with regard to primary structure. 7, 9, 15 Similar to Dok-1 and Dok-2, Dok-3 is also a negative regulator of PTKmediated signaling, despite being a relatively distant member of this subgroup. 11, [16] [17] [18] [19] However, mice lacking Dok-3 alone or Dok-1 and its closest homolog Dok-2 in combination do not develop aggressive tumors of hematopoietic cells. 7, 8, 18 In this study, we demonstrate that mice lacking Dok-1, Dok-2, and Dok-3 provide a model system for aggressive HS. Triple null mutant mice showed an early lethal phenotype that is associated with HS, and the tumor, which was transplantable, showed multiple organ invasion.
MATERIALS AND METHODS Mice

Dok-1
À/À Dok-2 À/À and Dok-3 À/À mice were generated as previously described.
7,20 Dok-1 Figure S1 ). Mice were genotyped by a standard PCR using DNA isolated from the tail tips. Primers to amplify the wild-type (WT) and targeted dok-1, dok-2, and dok-3 loci have been previously described. 7, 20 All mice were maintained in a mixed genetic background of strains 129/SvJ and C57BL/6 under pathogen-free conditions in the animal care facilities at Tokyo Medical and Dental University and The University of Tokyo. The experimental protocols have been approved by the animal ethics committees of the two institutions.
Histological Analysis
For hematoxylin and eosin (H&E) staining, tissue samples, aside from bones, were fixed in 10% neutral-buffered formalin, embedded in paraffin, sectioned, and stained. Bones were fixed similarly and decalcified in 14% EDTA solution for 3 days at room temperature with gentle stirring before staining with H&E. For immunohistochemistry using antibodies to Mac-2, PCNA, and Ki-67, paraffin sections were processed with 10 mM citrate buffer (pH 6.0) in a microwave (951C, 15 min) and subjected to standard immunohistochemical staining using the streptavidin-biotinperoxidase complex method. For immunohistochemistry using antibodies to F4/80, CD68, CD3, and B220, cryostat sections were fixed in 95% acetone at 41C for 20 min and were also subjected to standard immunohistochemical staining using the streptavidin-biotin-peroxidase complex method. The slides were counterstained with hematoxylin. Endogenous peroxidase activity was inactivated by incubation with 3% hydrogen peroxide in methanol (at room temperature for 15 min). The following antibodies were used: anti-Mac-2 rat monoclonal antibody (M3/38, Cedarlane, Burlington, ON, Canada; dilution 1:400); anti-F4/80 rat monoclonal antibody (BM8, BD Biosciences, San Diego, CA, USA; dilution 1:100); anti-CD68 rat monoclonal antibody (FA-11, Serotec, Kidlington, UK; dilution 1:100); anti-B220 rat monoclonal antibody (RA3-6B2, BD Biosciences; dilution 1:100); anti-CD3 hamster monoclonal antibody (145-2C11, BD Biosciences; dilution 1:100); anti-PCNA mouse monoclonal antibody (PC10, Dako, Glostrup, Denmark; dilution 1:100); and anti-Ki-67 rat monoclonal antibody (TEC-3, Dako; dilution 1:50). Only nonautolyzed tissues from moribund or recently deceased mice were subjected to histological analysis.
Microscopy
Sections were viewed using an AX80 microscope (Olympus, Tokyo, Japan) with either a Â 20 or Â 40 PlanApo objective. Images were captured using a DP70 digital camera and DP Controller software (Olympus).
Transplantation
Nucleated bone marrow cells or splenocytes (2 Â 10 6 cells) prepared from the donor were intravenously injected into lethally irradiated WT recipient mice. Irradiation was performed using an IBL-437C instrument ( 137 Cs, CIS BioInternational, Gif-sur-Yvette, France) at 9 Gy, and no survival was observed beyond 2 weeks after irradiation in the absence of transplantation. In Figure 3 , TKO and WT mice at 78-88 weeks of age were used as donors and WT mice at 8-16 weeks of age were used as recipients. In Figure 4c , TKO and WT mice at 6-10 weeks of age were used as donors and WT mice at 8-16 weeks of age were used as recipients: these recipient mice were killed 8-10 weeks after transplantation and histological studies were performed.
Bone Marrow-Derived Macrophages
Bone marrow cells were cultured in DME medium containing 100 ng/ml of recombinant murine macrophage colonystimulating factor (M-CSF, PeproTech, Rocky Hill, NJ, USA) and 15% FCS. After 7 days of culture, adherent cells were maintained in the absence of M-CSF for 16 h and were used as bone marrow-derived macrophages.
Cell Viability Assay
Bone marrow-derived macrophages (1 Â 10 4 ) were plated in 96-well plates in quadruplicate, cultured in RPMI-1640 medium containing 15% FCS in the presence or absence of M-CSF or recombinant murine granulocyte-macrophage colony-stimulating factor (GM-CSF, PeproTech) for 5 days.
Cells were then treated with 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT, Sigma, St Louis, MO, USA) for 4 h at 371C, cellular formazan product was dissolved with acidic isopropanol, and the absorbance at 570 nm was measured spectrophotometrically to evaluate viable cells using an Emax microplate reader (Molecular Devices, Sunnyvale, CA, USA).
RESULTS
TKO Mice Succumb to HS
To examine whether Dok-1, Dok-2, and Dok-3 cooperatively suppress malignant tumor formation in vivo, we generated TKO mice. These mice were born at the expected Mendelian frequency without any abnormality in appearance evident by visual inspection. However, nearly half (15 of 33) of the TKO mice died between 14-51 weeks after birth, whereas all WT and Dok-1 À/À Dok-2 À/À mice as well as all Dok-3 À/À mice but one remained alive (Figure 1a ). To gain insight into the early lethal phenotype of TKO mice, we first performed conventional histological studies. H&E staining of tissue sections revealed that TKO mice, but neither the other mutants nor the WT controls, showed a markedly high incidence (24 of 41) of large cell tumors at o65 weeks of age, characterized by the accumulation of abnormal cells with histiocytic morphology in the bone marrow, spleen, and/or liver (Figure 1b) . The aberrant cells are distinguished morphologically from other hematopoietic cells by their round shape, prominent nuclear atypia, and eosinophilic cytoplasm, features that The percentage of mice that are HS positive in the BM, spleen, and/or liver was determined for each genotype and condition (dead/moribund or not) and is presented along with the exact fraction in parenthesis. Dead/moribund TKO mice at 52-64 weeks of age showed a significantly higher rate of HS positivity than TKO mice that were neither dead nor moribund (control). No tumor was observed in the age-matched WT mice. TKO mice that died or became moribund before 52 weeks of age also showed a high rate of HS positivity. Fischer's exact test was used to calculate the statistical significance. *Po0.05.
A model of aggressive histiocytic sarcoma R Mashima et al are characteristic of HS tumor cells (Figure 1b) . Moreover, tumors showed monotonous morphology with tissue destruction and mass lesions, suggesting a malignant transformation ( Figure 1b and Supplementary Figure S2) . Immunohistochemical staining revealed the abnormal cells to be positive for the histiocyte/macrophage markers, Mac-2, F4/80, and CD68, but negative for the lymphocyte markers, CD3 and B220, consistent with the interpretation that these tumor cells represent HS (Figure 1c) . 21, 22 In addition, these cells stained positively with antibodies to MHC class II molecules, a marker of antigen-presenting cells including macrophages (Supplementary Figure S3) . Further immunohistochemical examination showed HS cells to stain positively with antibodies to PCNA and Ki67, confirming that these cells are proliferative (Figure 1c) .
As most patients with HS die of progressive disease, we examined whether HS is associated with the early lethal phenotype of TKO mice. As shown in Figure 1d , 9 of 11 moribund or dead mice at o52 weeks of age that could be necropsied bore HS in the bone marrow, spleen, and/or liver. Furthermore, no similar cells were found in WT mice even at 52-64 weeks of age. By contrast, 12 of 17 dead or moribund mice that could be necropsied at matched age developed HS, whereas only 3 of 13 nondead/moribund mice were positive for the tumor, indicating a significant link of HS with the lethal phenotype of TKO mice (Figure 1d ).
HS Developed in TKO Mice is Highly Invasive and Transplantable
To evaluate the tumorigenic potential of HS developed in TKO mice, we wished to know whether the tumors spread into multiple organs. We examined six organs, the bone marrow, spleen, lung, skeletal muscle (femoral muscle), liver, and kidney. In all, 17 of the 21 tumor-bearing TKO mice at 25-66 weeks of age whose organs could be analyzed at necropsy showed multiple organ spread of the tumor (Figure 2a) . As nearly all (20 of 21) TKO mice had HS in the bone marrow, this tissue might be the primary site of tumorigenesis in these mice (Figure 2b) . Moreover, the majority (11 of 20) of bone marrow lesions were associated with osteolytic and direct invasions to the skeletal muscle (Figure 2b and c) , indicating a strong invasiveness of the tumor. Next, to further examine the tumorigenic potential of HS developed in TKO mice, we examined whether the tumor was transplantable. Cells prepared from bone marrow or spleen of TKO mice or WT controls at 78-88 weeks of age were transplanted into lethally irradiated WT recipients intravenously. The mice transplanted with TKO cells from HS-positive tissues died within 10 weeks after transplantation, whereas control recipients that had been transplanted with cells from WT animals or from HS-negative sources of TKO animals survived, suggesting that the tumor was transplantable (Figure 3a) . Indeed, histological study con- A model of aggressive histiocytic sarcoma R Mashima et al firmed that almost all the recipient mice that had been transplanted with TKO cells from HS-positive animals and could be necropsied had HS in their bone marrow (10 of 11) and spleen (9 of 9) (Figure 3b and c) . Furthermore, HS was not observed in control recipients that had been transplanted with WT cells (n ¼ 11) or TKO cells from HS-negative sources (n ¼ 13). We conclude that the malignant cell type that develops in TKO mice is highly invasive and transplantable.
TKO Mice Show Abnormal Accumulation of Macrophages in the Lung
During the course of histological analysis of TKO mice, we frequently found abnormal accumulation of Mac-2-positive macrophages in the lung (Figure 4a) . These macrophages had a large cytoplasm without nuclear atypia and were not associated with tissue destruction, suggesting a nontumorigenic nature. Almost all (13 of 14) TKO mice, but neither Dok-1
À/À (0 of 11) mice nor the WT controls (0 of 9), exhibited such abnormal proliferation of macrophages, which was uncorrelated with the presence or absence of HS at 50-59 weeks of age (Figure 4b) . The incidence of macrophage accumulation in the lung was intermediate (3 of 8) in age-matched Dok-3 À/À mice. Although development of lung adenocarcinoma, but not aggressive HS, has recently been reported in mice lacking Dok-1, Dok-2, and/or Dok-3 on a pure 129S1/SvImj genetic background even at the age of 11-15 months, 23 in this study mice mu- tated in the same genes, but on a 129/SvJ and C57BL/6 mixed background, did not exhibit elevated incidence of lung adenocarcinoma. These different findings are likely due to the difference in the genetic backgrounds. When bone marrow cells of TKO mice at 6-10 weeks of age were transplanted into lethally irradiated recipients, we invariably observed macrophage accumulation in the lung within 10 weeks after transplantation (n ¼ 4), but not when bone marrow cells were transplanted from WT controls (Figure 4c) . Similarly, the histological study of TKO mice at 8-12 weeks of age, before the onset of observable HS, confirmed abnormal proliferation of macrophages in the lung of all mutant mice (8 of 8) but not in WT controls (0 of 8) (Figure 4d showed such accumulation of macrophages. Given that Dok-1 and Dok-2 negatively regulate proliferation of bone marrow-derived macrophages in vitro, 7 these findings suggest that Dok-1, Dok-2, and Dok-3 cooperatively inhibit the proliferation of macrophages. 
Dok
DISCUSSION
In this study, we have established that combined ablation of the adaptor proteins Dok-1, Dok-2, and Dok-3 has profound phenotypic consequences in mice. TKO mice, but not WT controls, develop and succumb to aggressive HS with multiple organ invasion. Although individual Dok proteins have the ability to inhibit PTK-mediated oncogenic signaling, [5] [6] [7] [8] [9] 16 in this study mice lacking Dok-3 alone or Dok-1 and Dok-2 in combination did not develop aggressive tumors. The simplest interpretation for these data is that Dok proteins 1-3 can each suppress the aggressive transformation of HS. In addition, combined loss of Dok-1, Dok-2, and Dok-3 causes abnormal proliferation of macrophages in the lung, observable before the onset of morphologically recognizable HS. By contrast, combined ablation of Dok-1 and Dok-2 did not cause accumulation of macrophages in the lung. Although deficiency in Dok-3 caused abnormal proliferation of macrophages in the lung, the incidence was low. Therefore, the data suggest that these Dok proteins mutually compensate to inhibit the proliferation of macrophages. Indeed, our in vitro assay revealed that these proteins cooperatively downregulate proliferative response of macrophages on M-CSF or GM-CSF stimulation. Given that histiocytes are tissue-resident macrophages and HS is believed to arise from macrophage lineages, it is likely that the enhanced proliferative capacity of macrophages in mice lacking Dok-1, Dok-2, and Dok-3 contributes to the development of HS. In general, Dok family proteins are believed to be activated as adaptors by tyrosine phosphorylation. 9 It was previously demonstrated that Lyn is required for the tyrosine phosphorylation of Dok-1 and Dok-3 in B cells (in which Dok-2 is typically undetectable) on B-cell receptor signaling, 6, 27 suggesting that Lyn may activate these Dok proteins as negative regulators to suppress HS. Indeed, it has been reported that Lyn is expressed in macrophages, and that bone marrowderived macrophages from Lyn-deficient mice showed enhanced growth responses to M-CSF and GM-CSF. 28 Furthermore, mice lacking Lyn develop macrophage tumors, which may be related to HS. 28 Unlike TKO mice, however, Lyn-deficient mice additionally develop severe renal disease. 29 As mentioned above, HS in humans is an aggressive malignancy of unknown etiology and there remains a need for realistic animal models. Mouse models that have been reported for HS frequently show multiple lesions including lymphomas and severe renal failure. For example, the majority of mice lacking Pten, Ink4A, and Arf in combination develop both lymphoblastic B-cell lymphomas and HS with virtually the same incidence. 30 Similarly, mice lacking the cell-cycle regulator p21 develop a variety of tumors, including HS and B-cell lymphomas, and also suffered from severe renal failure, 31 unlike TKO mice. The syndrome elicited in mice lacking all the three proteins, Dok-1, Dok-2, and Dok-3, more specifically resembles the disease found in humans and hence may serve as a useful model for the study of HS. Although elucidation of the mechanisms by which the ablation of Dok proteins specifically causes HS and how the tumor gains its aggressive phenotype awaits further studies, such studies will help unveil the hidden etiology of this rare aggressive human malignancy. 
